Three Key Takeaways from the 43rd Annual J.P. Morgan Healthcare Conference
Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ground floor.
Prioritize Provider Data for Seamless M&A Success
Health systems preparing for an M&A, or even those not immediately considering one, must prioritize a robust workforce data strategy. This approach is essential for navigating today’s increasingly frequent healthcare consolidations.
presented by
Why Your Patients Are Leaving and How to Stop It
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Valuation of Biotech Transactions: Trends, Drivers, and Implications
Current trends are driven by various strategic and financial considerations from both established pharmaceutical companies and development-stage biotech firms. Understanding the valuation and accounting implications of these transactions are crucial for stakeholders to navigate the complex landscape effectively.
PerkinElmer scoops up German diagnostics company for $1.3B
It's a sign of the times: PerkinElmer has acquired Euroimmun, a diagnostics company with a strong market presence in China and other emerging markets.
Should Big Pharma spend more on marketing than R&D?
Nine out of 10 large pharma companies spend more on marketing than they do on R&D. It's a statistic often cited as a sign of industry greed, but it may be the best way to foster real innovation.